Skip to content

Verapamil

Calan, Calan Sr, Covera-hs, Isoptin, Verapamil, Verelan, Verelan Pm (verapamil) is a small molecule pharmaceutical. Verapamil was first approved as Calan on 1982-01-01. It is used to treat atrial fibrillation, atrial flutter, hypertension, myocardial infarction, and supraventricular tachycardia amongst others in the USA. The pharmaceutical is active against voltage-dependent L-type calcium channel subunit alpha-1C and voltage-dependent L-type calcium channel subunit alpha-1S. In addition, it is known to target sodium leak channel non-selective protein, potassium voltage-gated channel subfamily A member 10, Voltage-dependent L-type calcium channel subunit alpha-1F, two pore calcium channel protein 2, G protein-activated inward rectifier potassium channel 2, cytochrome P450 3A4, voltage-dependent L-type calcium channel subunit alpha-1D, two pore calcium channel protein 1, equilibrative nucleoside transporter 4, potassium voltage-gated channel subfamily A member 7, and potassium voltage-gated channel subfamily C member 2.
Trade Name Calan, Calan Sr, Covera-hs, Isoptin, Verapamil, Verelan, Verelan Pm
Common Name Verapamil
Indication atrial fibrillation, atrial flutter, hypertension, myocardial infarction, supraventricular tachycardia, variant angina pectoris
Drug Class Coronary vasodilators (verapamil type)
Verapamil
Get full access now